Stem definition | Drug id | CAS RN |
---|---|---|
1622 | 56-87-1 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
None | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Foetal growth restriction | 42.64 | 17.87 | 16 | 2982 | 6551 | 46676513 |
Infantile apnoea | 32.69 | 17.87 | 8 | 2990 | 768 | 46682296 |
Selective eating disorder | 26.27 | 17.87 | 8 | 2990 | 1737 | 46681327 |
Stomatitis | 24.74 | 17.87 | 26 | 2972 | 68271 | 46614793 |
Cerebral haemorrhage | 22.83 | 17.87 | 17 | 2981 | 28354 | 46654710 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|
Source | Code | Description |
---|---|---|
ATC | B05XB03 | BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTION ADDITIVES Amino acids |
ATC | V03AF11 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment |
CHEBI has role | CHEBI:27027 | trace elements |
CHEBI has role | CHEBI:35623 | antiepileptic |
CHEBI has role | CHEBI:50733 | nutritional supplement |
CHEBI has role | CHEBI:75771 | mus musculus metabolite |
CHEBI has role | CHEBI:75772 | baker's yeast metabolite |
CHEBI has role | CHEBI:76924 | plant metabolites |
CHEBI has role | CHEBI:76971 | e.coli metabolites |
CHEBI has role | CHEBI:77746 | h. sapiens metabolites |
CHEBI has role | CHEBI:84735 | algal metabolites |
CHEBI has role | CHEBI:83056 | daphnia magna metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Partial Central Diabetes Insipidus | indication | ||
Classical phenylketonuria | contraindication | 7573000 | |
Poisoning by digitalis glycoside | contraindication | 12876009 | |
Sarcoidosis | contraindication | 31541009 | DOID:11335 |
End stage renal disease | contraindication | 46177005 | DOID:784 |
Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
Heart disease | contraindication | 56265001 | DOID:114 |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Ventricular fibrillation | contraindication | 71908006 | |
Hypercalciuria | contraindication | 71938000 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Kidney stone | contraindication | 95570007 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 1.99 | acidic |
pKa2 | 10.46 | Basic |
pKa3 | 9.86 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Glutathione reductase, mitochondrial | Enzyme | Ki | 4.26 | CHEMBL |
ID | Source |
---|---|
4018682 | VUID |
N0000146993 | NUI |
D02304 | KEGG_DRUG |
657-27-2 | SECONDARY_CAS_RN |
4018682 | VANDF |
4018689 | VANDF |
C0024337 | UMLSCUI |
CHEBI:133538 | CHEBI |
LYS | PDB_CHEM_ID |
CHEMBL8085 | ChEMBL_ID |
CHEMBL2105886 | ChEMBL_ID |
D008239 | MESH_DESCRIPTOR_UI |
DB00123 | DRUGBANK_ID |
724 | IUPHAR_LIGAND_ID |
6166 | INN_ID |
K3Z4F929H6 | UNII |
5962 | PUBCHEM_CID |
6536 | RXNORM |
10705 | MMSL |
233693 | MMSL |
42619 | MMSL |
5002 | MMSL |
d00488 | MMSL |
000931 | NDDF |
005151 | NDDF |
418834008 | SNOMEDCT_US |
734658000 | SNOMEDCT_US |
75799006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0180 | INJECTION | 464 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0184 | INJECTION, EMULSION | 464 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0188 | INJECTION | 464 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0194 | INJECTION | 464 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-0198 | INJECTION | 348 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0202 | INJECTION | 464 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0206 | INJECTION | 464 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0210 | INJECTION | 464 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-0214 | INJECTION | 464 mg | INTRAVENOUS | NDA | 20 sections |
Travasol | HUMAN PRESCRIPTION DRUG LABEL | 15 | 0338-0644 | INJECTION | 580 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1089 | INJECTION | 247 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1091 | INJECTION | 247 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1099 | INJECTION | 290 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1101 | INJECTION | 290 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1113 | INJECTION | 247 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1115 | INJECTION | 247 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1123 | INJECTION | 290 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1125 | INJECTION | 290 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1133 | INJECTION | 247 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1134 | INJECTION | 247 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1137 | INJECTION | 290 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX | HUMAN PRESCRIPTION DRUG LABEL | 16 | 0338-1138 | INJECTION | 290 mg | INTRAVENOUS | NDA | 21 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1142 | INJECTION | 159 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1144 | INJECTION | 247 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1145 | INJECTION | 247 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1147 | INJECTION | 290 mg | INTRAVENOUS | NDA | 20 sections |
CLINIMIX E | HUMAN PRESCRIPTION DRUG LABEL | 21 | 0338-1148 | INJECTION | 290 mg | INTRAVENOUS | NDA | 20 sections |
Effervescent Potassium Chloride | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0603-3508 | TABLET, EFFERVESCENT | 1.50 g | ORAL | unapproved drug other | 17 sections |
Kabiven | HUMAN PRESCRIPTION DRUG LABEL | 24 | 63323-712 | INJECTION, EMULSION | 263 mg | INTRAVENOUS | NDA | 25 sections |
Perikabiven | HUMAN PRESCRIPTION DRUG LABEL | 24 | 63323-714 | INJECTION, EMULSION | 187 mg | INTRAVENOUS | NDA | 25 sections |